Magro, F., Lopes, S., Silva, M., Coelho, R., Portela, F., Branquinho, D., . . . Carneiro, F. (2019). Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.
Chicago Style CitationMagro, Fernando, et al. Soluble Human Suppression of Tumorigenicity 2 Is Associated With Endoscopic Activity in Patients With Moderate-to-severe Ulcerative Colitis Treated With Golimumab. 2019.
MLA CitationMagro, Fernando, et al. Soluble Human Suppression of Tumorigenicity 2 Is Associated With Endoscopic Activity in Patients With Moderate-to-severe Ulcerative Colitis Treated With Golimumab. 2019.
Note: citation formatting may not correspond 100% to that defined by the respective standard, to manage citations it is recommended to use the software Zotero
, which allows the automatic upload of Oasisbr references.